启动抗CTLA-4治疗后早期黑色素瘤脑转移行立体定向放射外科与颅内控制改善相关
末次伊匹木单抗剂量后5.5个月内接受SRS者颅内控制显著优于超过5.5个月者,且SRS前外周血淋巴细胞绝对计数>1000/µL与颅内复发风险降低相关。
要点
- 末次伊匹木单抗后5.5个月内行SRS者颅内控制优于超过5.5个月者。
- 两组总生存无差异。
- SRS前淋巴细胞绝对计数>1000/µL者颅内复发风险降低。
核心结论
- 开始伊匹木单抗治疗后新发脑转移的患者,在末次伊匹木单抗剂量后5.5个月内接受SRS较超过5.5个月者颅内疾病控制更好。
- SRS前外周血淋巴细胞绝对计数较高与颅内疾病控制改善相关。
研究设计与样本
- 所有患者SRS前均获取全血细胞计数,主要结局为颅内疾病控制和总生存。
主要发现
- 中位随访15.5个月。
- MD Anderson队列中,末次伊匹木单抗剂量后超过5.5个月接受SRS者(n=20)颅内控制显著差于5.5个月内接受SRS者(n=51),中位3.63个月对8.09个月,风险比2.07(95%CI 1.03-4.16,p=0.041)。
- 两组总生存无差异。
- 颅内控制改善在Yale-New Haven Hospital独立验证队列28例患者中得到确认。
- SRS前淋巴细胞绝对计数>1000/µL者较≤1000/µL者颅内复发风险降低(HR 0.46,95%CI 0.23-0.94,p=0.03)。
临床怎么用
- 对于伊匹木单抗治疗中出现新发脑转移的黑色素瘤患者,可考虑在末次伊匹木单抗剂量后5.5个月内尽早行SRS以改善颅内控制。
- SRS前可参考外周血淋巴细胞绝对计数评估颅内复发风险。
局限性
- 本研究为多机构回顾性分析,非随机对照设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Numerous studies suggest that radiation can boost antitumor immune response by stimulating release of tumor-specific antigens. However, the optimal timing between radiotherapy and immune checkpoint blockade to achieve potentially synergistic benefits is unclear. MATERIAL AND METHODS: Multi-institutional retrospective analysis was conducted of ninety-nine metastatic melanoma patients from 2007 to 2014 treated with ipilimumab who later received stereotactic radiosurgery (SRS) for new brain metastases that developed after starting immunotherapy. All patients had complete blood count acquired before SRS. Primary outcomes were intracranial disease control and overall survival (OS). RESULTS: The median follow-up time was 15.5months. In the MD Anderson cohort, patients who received SRS after 5.5months (n=20) of their last dose of ipilimumab had significantly worse intracranial control than patients who received SRS within 5.5months (n=51) (median 3.63 vs. 8.09months; hazard ratio [HR] 2.07, 95% confidence interval [CI] 1.03-4.16, p=0.041). OS was not different between the two arms. The improvement in intracranial control was confirmed in an independent validation cohort of 28 patients treated at Yale-New Haven Hospital. Circulating absolute lymphocyte count before SRS predicted for treatment response as those with baseline counts >1000/µL had reduced risk of intracranial recurrence compared with those with ≤1000/µL (HR 0.46, 95% CI 0.0.23-0.94, p=0.03). CONCLUSIONS: In this multi-institutional study, patients who received SRS for new brain metastases within 5.5months after ipilimumab therapy had better intracranial disease control than those who received SRS later. Moreover, higher circulating lymphocyte count was associated with improved intracranial disease control.
引用
- An Y, Jiang W, Kim BYS, et al. Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol. 2017. PMID: 28916225. doi:10.1016/j.radonc.2017.08.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。